Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of whole virion influenza vaccines
NL-OMON22232Not yet recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of ARCT-2138 and Placebo-COD Research Private Ltd in influenza, sponsored by National Institute for Public Health and the Environment. Primary endpoints: Incidence of systemic adverse events and Incidence of local adverse events. Planned start Apr 2011; status: not yet recruiting.
02
Drugs
ARCT-2138Placebo-COD Research Private Ltd
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON22232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22232.